Nature Medicine, Published online: 19 February 2026; doi:10.1038/s41591-026-04238-4 In a case series of five patients with treatment-refractory antisynthetase syndrome and five patients with treatment-refractory systemic sclerosis, bispecific T cell engagers blinatumomab and teclistamab improved disease activity and were well tolerated.
Nature Medicine, Published online: 19 February 2026;
doi:10.1038/s41591-026-04238-4
In a case series of five patients with treatment-refractory antisynthetase syndrome and five patients with treatment-refractory systemic sclerosis, bispecific T cell engagers blinatumomab and teclistamab improved disease activity and were well tolerated.
— Source: Nature Medicine (https://www.nature.com/articles/s41591-026-04238-4)